VCA Inc. (NASDAQ:WOOF) – Research analysts at Northcoast Research increased their FY2016 EPS estimates for shares of VCA in a research note issued on Wednesday. Northcoast Research analyst E. Snyder now anticipates that the brokerage will earn $2.97 per share for the year, up from their previous estimate of $2.96. Northcoast Research also issued estimates for VCA’s Q2 2017 earnings at $0.99 EPS and FY2017 earnings at $3.43 EPS.
WOOF has been the topic of a number of other research reports. Zacks Investment Research upgraded VCA from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a report on Friday, July 29th. Jefferies Group reiterated a “hold” rating on shares of VCA in a report on Friday, August 5th. Finally, Bank of America Corp. initiated coverage on VCA in a report on Thursday. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $71.75.
Shares of VCA (NASDAQ:WOOF) traded up 0.19% during midday trading on Thursday, reaching $68.01. The company’s stock had a trading volume of 409,432 shares. The company has a 50-day moving average price of $70.58 and a 200-day moving average price of $65.64. VCA has a 12 month low of $44.00 and a 12 month high of $73.69. The firm has a market cap of $5.50 billion, a price-to-earnings ratio of 24.26 and a beta of 1.30.
VCA (NASDAQ:WOOF) last announced its earnings results on Wednesday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.05. The firm earned $653.50 million during the quarter, compared to analysts’ expectations of $637.18 million. VCA had a return on equity of 16.86% and a net margin of 9.93%. The company’s revenue was up 19.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.70 earnings per share.
In related news, Director John B. Chickering, Jr. sold 2,302 shares of VCA stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $70.85, for a total value of $163,096.70. Following the sale, the director now owns 10,992 shares of the company’s stock, valued at approximately $778,783.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Arthur J. Antin sold 34,000 shares of VCA stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $69.03, for a total value of $2,347,020.00. Following the completion of the sale, the chief operating officer now directly owns 89,691 shares in the company, valued at approximately $6,191,369.73. The disclosure for this sale can be found here. Insiders own 4.60% of the company’s stock.
A number of large investors have recently made changes to their positions in WOOF. Victory Capital Management Inc. raised its stake in shares of VCA by 284.6% in the second quarter. Victory Capital Management Inc. now owns 1,422,709 shares of the company’s stock worth $96,189,000 after buying an additional 1,052,773 shares in the last quarter. Norges Bank purchased a new stake in shares of VCA during the fourth quarter worth about $44,158,000. Congress Asset Management Co. MA purchased a new stake in shares of VCA during the second quarter worth about $38,961,000. William Blair Investment Management LLC purchased a new stake in shares of VCA during the second quarter worth about $36,329,000. Finally, FMR LLC raised its stake in shares of VCA by 34.4% in the second quarter. FMR LLC now owns 1,542,771 shares of the company’s stock worth $104,307,000 after buying an additional 394,955 shares in the last quarter. 91.17% of the stock is currently owned by institutional investors and hedge funds.
VCA Inc is an animal healthcare company. The Company operates through five segments. Its Animal Hospital segment provides veterinary services for companion animals and sells related retail and pharmaceutical products. Its Laboratory segment provides diagnostic laboratory testing services for veterinarians, both associated with its animal hospitals and those independent of the Company.
Receive News & Ratings for VCA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VCA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.